We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AiCuris’ Novel HSV Compound AIC316 Shows Efficacy in Phase II
News

AiCuris’ Novel HSV Compound AIC316 Shows Efficacy in Phase II

AiCuris’ Novel HSV Compound AIC316 Shows Efficacy in Phase II
News

AiCuris’ Novel HSV Compound AIC316 Shows Efficacy in Phase II

Read time:
 

Phase II results for AiCuris' novel non-nucleosidic herpes simplex virus (HSV) inhibitor AIC316 reveal safety and efficacy in persons with genital herpes.

The data were presented at the 19th ISSTDR Meeting (International Society for Sexually Transmitted Diseases Research) in Quebec, Canada, by the coordinating investigator of the trial, Professor Anna Wald from the University of Washington and Fred Hutchinson Cancer Research Center in Seattle, USA.

156 HSV-2 positive participants (105 women and 51 men) were randomized between May 2010 and October 2010 at seven sites in the US.

The goal of the trial was to compare the efficacy of four different doses of AIC316 (5, 25, and 75 mg once daily, or 400 mg once weekly) and placebo with respect to the suppression of HSV shedding. All participants received the study drug or placebo daily or weekly for 4 weeks.

AIC316 was safe and well tolerated at all doses administered and led to a significant reduction of viral shedding in a dose dependent manner.

The strongest treatment effect was seen in the 400 mg once weekly and the 75 mg once daily dosing groups. Moreover, AIC316 led to a significant reduction of the amount of HSV found.

This highly suppressive effect of AIC316 on viral replication also correlated with a significant clinical benefit: the proportion of days with reported genital lesions was reduced from 13,7 % to 1,1 %; the number of recurrences was substantially reduced as well.

”We are very pleased with these data as HSV therapy has not seen much innovation in more than a decade. Our data confirm an excellent antiviral efficacy in humans, a clear dose response and an overall good safety profile. The innovative trial design that used shedding was important to show clearly the benefit of our drug and identify doses for further development”, says Prof. Helga Rübsamen-Schaeff, CEO at AiCuris.

“The significant clinical benefit of reduced lesions and recurrences combined with a good safety profile are very encouraging for the further development of our drug” adds Dr. Marie-Paule Richard, CMO at AiCuris.

Advertisement